DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference

Rhea-AI Summary

DBV Technologies (Ticker: DBVT) announced CEO Daniel Tassé will participate in a virtual fireside chat at the SVB Leerink Global Partners Healthcare Conference on February 24, 2021, at 8 am ET. The event will be accessible via a live webcast on DBV's website, with a replay available post-event. The company is focused on developing Viaskin™, a proprietary technology for immunotherapy targeting food allergies, including ongoing trials for Viaskin Peanut. DBV Technologies operates globally, with headquarters in Montrouge, France, and offices in the USA.

Montrouge, France, February 19, 2021

DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the virtual SVB Leerink Global Partners Healthcare Conference on Wednesday, February 24^th at 8am ET.

A live webcast of the fireside chat at the SVB Leerink Global Partners Healthcare Conference will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com

Attachment

• PDF Version

FAQ

When is DBV Technologies participating in the SVB Leerink Global Partners Healthcare Conference?

DBV Technologies will participate in the SVB Leerink Global Partners Healthcare Conference on February 24, 2021.

Who will represent DBV Technologies at the healthcare conference?

CEO Daniel Tassé will represent DBV Technologies at the SVB Leerink Global Partners Healthcare Conference.

What is the focus of DBV Technologies' current projects?

DBV Technologies focuses on developing Viaskin™, a technology platform for immunotherapy targeting food allergies.

Where can I watch the DBV Technologies presentation from the conference?

The presentation will be available via a live webcast on DBV Technologies' website, with a replay accessible after the event.

What is the ticker symbol for DBV Technologies?

The ticker symbol for DBV Technologies on the Nasdaq is DBVT.